According to newly released data from analytics firm MediaRadar, drugmakers spent nearly $500 million on advertising for weight loss and diabetes drugs for the U.S. market during the first seven months of 2023.
This ad spend is up 20% from the same time frame last year.
The advertising boost likely stemmed from drug makers attempting to capitalize off the surging popularity of weight loss semaglutide injections like Wegovy and Ozempic.
U.S. doctors reportedly wrote a total of 9 million prescriptions for the aforementioned drugs during the last three months of 2022 alone.
